Lumira Ventures

Lumira Ventures is a venture capital firm based in Toronto, Ontario, specializing in investments in emerging, mid, and late-stage companies within the healthcare and life sciences sectors. Founded in 2007, the firm primarily focuses on biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies, with a strong emphasis on opportunities in North America, particularly Canada and the United States. Lumira Ventures typically invests between 5 million and 15 million in its portfolio companies, which currently includes over 30 active investee firms. The firm is dedicated to maximizing the value of its investments through active board participation and facilitating access to additional funding sources, strategic partners, and market opportunities. With a track record of investing in more than 100 healthcare companies since its inception, Lumira Ventures aims to support entrepreneurial management teams in addressing significant unmet needs within the healthcare landscape.

Gerry Brunk, MBA

Managing Director

Paolo Di Giorgio

Founder, CEO and Managing Director, Rome

Lu Han, Ph.D.

Partner

Daniel Hetu

Managing Director

Jacki Jenuth

Partner and COO

Vasco Larcina

CFO

Alice Luo

Analyst

David Novak

Venture Partner

Suman Rao

Senior Associate

Benjamin Rovinski, Ph.D.

Managing Director

Nikhil Thatte

Partner

Brian J. Underdown, Ph.D.

Venture Partner

Peter van der Velden, MBA, M.Sc.

Founder and Managing General Partner

Benjamin Rovinski Ph.D

Managing Director

BAYE GALLIGAN, MA, HBA

Director of Research

Past deals in Minnesota

HistoSonics

Series C in 2020
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

HistoSonics

Series C in 2019
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.